The Relationship Between the Human Immunodeficiency Virus-1 Transmission Network and the HIV Care Continuum in Los Angeles County.
Cox proportional hazard
HIV
care continuum
cluster
gamma frailty
molecular epidemiology
transmission network
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
13
11
2019
accepted:
03
02
2020
pubmed:
6
2
2020
medline:
28
4
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Public health action combating human immunodeficiency virus (HIV) includes facilitating navigation through the HIV continuum of care: timely diagnosis followed by linkage to care and initiation of antiretroviral therapy to suppress viral replication. Molecular epidemiology can identify rapidly growing HIV genetic transmission clusters. How progression through the care continuum relates to transmission clusters has not been previously characterized. We performed a retrospective study on HIV surveillance data from 5226 adult cases in Los Angeles County diagnosed from 2010 through 2014. Genetic transmission clusters were constructed using HIV-TRACE. Cox proportional hazard models were used to estimate the impact of transmission cluster growth on the time intervals between care continuum events. Gamma frailty models incorporated the effect of heterogeneity associated with genetic transmission clusters. In contrast to our expectations, there were no differences in time to the care continuum events among individuals in clusters with different growth dynamics. However, upon achieving viral suppression, individuals in high growth clusters were slower to experience viral rebound (hazard ratio 0.83, P = .011) compared with individuals in low growth clusters. Heterogeneity associated with cluster membership in the timing to each event in the care continuum was highly significant (P < .001), with and without adjustment for transmission risk and demographics. Individuals within the same transmission cluster have more similar trajectories through the HIV care continuum than those across transmission clusters. These findings suggest molecular epidemiology can assist public health officials in identifying clusters of individuals who may benefit from assistance in navigating the HIV care continuum.
Sections du résumé
BACKGROUND
Public health action combating human immunodeficiency virus (HIV) includes facilitating navigation through the HIV continuum of care: timely diagnosis followed by linkage to care and initiation of antiretroviral therapy to suppress viral replication. Molecular epidemiology can identify rapidly growing HIV genetic transmission clusters. How progression through the care continuum relates to transmission clusters has not been previously characterized.
METHODS
We performed a retrospective study on HIV surveillance data from 5226 adult cases in Los Angeles County diagnosed from 2010 through 2014. Genetic transmission clusters were constructed using HIV-TRACE. Cox proportional hazard models were used to estimate the impact of transmission cluster growth on the time intervals between care continuum events. Gamma frailty models incorporated the effect of heterogeneity associated with genetic transmission clusters.
RESULTS
In contrast to our expectations, there were no differences in time to the care continuum events among individuals in clusters with different growth dynamics. However, upon achieving viral suppression, individuals in high growth clusters were slower to experience viral rebound (hazard ratio 0.83, P = .011) compared with individuals in low growth clusters. Heterogeneity associated with cluster membership in the timing to each event in the care continuum was highly significant (P < .001), with and without adjustment for transmission risk and demographics.
CONCLUSIONS
Individuals within the same transmission cluster have more similar trajectories through the HIV care continuum than those across transmission clusters. These findings suggest molecular epidemiology can assist public health officials in identifying clusters of individuals who may benefit from assistance in navigating the HIV care continuum.
Identifiants
pubmed: 32020172
pii: 5722890
doi: 10.1093/cid/ciaa114
pmc: PMC7904072
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e384-e391Subventions
Organisme : NIAID NIH HHS
ID : K01 AI110181
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI135992
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Infect Dis. 2010 May 15;201(10):1488-97
pubmed: 20384495
J Infect Dis. 2018 Nov 5;218(12):1943-1953
pubmed: 30010850
PLoS Pathog. 2017 Jan 9;13(1):e1006000
pubmed: 28068413
Lancet. 2019 Jun 15;393(10189):2428-2438
pubmed: 31056293
J Public Health Manag Pract. 2014 Nov-Dec;20(6):598-607
pubmed: 24253405
PLoS Comput Biol. 2012;8(6):e1002552
pubmed: 22761556
AIDS. 2004 Mar 26;18(5):719-28
pubmed: 15075506
JAMA. 2018 Apr 24;319(16):1657-1658
pubmed: 29630701
Lancet HIV. 2019 Mar;6(3):e164-e172
pubmed: 30765313
J Infect Dis. 2015 Mar 15;211(6):926-35
pubmed: 25312037
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4425-9
pubmed: 15767575
Nat Commun. 2019 Dec 19;10(1):5788
pubmed: 31857582
AIDS. 2009 Jan 14;23(2):225-32
pubmed: 19098493
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
Curr Opin HIV AIDS. 2019 May;14(3):213-220
pubmed: 30882486
Lifetime Data Anal. 1995;1(3):255-73
pubmed: 9385105
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
AIDS Res Hum Retroviruses. 2019 Apr;35(4):368-375
pubmed: 30403157
Lancet HIV. 2016 May;3(5):e231-8
pubmed: 27126490
J Infect Dis. 2020 Mar 28;221(8):1321-1330
pubmed: 31028702
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet HIV. 2018 Jun;5(6):e309-e316
pubmed: 29893244
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):444-51
pubmed: 26302431
MMWR Morb Mortal Wkly Rep. 2018 Mar 22;68(11):267-272
pubmed: 30897075
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
AIDS Res Ther. 2016 Nov 8;13:35
pubmed: 27826353
Lifetime Data Anal. 1998;4(4):329-54
pubmed: 9880994
Mol Biol Evol. 2018 Jul 1;35(7):1812-1819
pubmed: 29401317
Stat Methods Med Res. 1994;3(3):227-43
pubmed: 7820293
PLoS Med. 2008 Mar 18;5(3):e50
pubmed: 18351795
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):543-550
pubmed: 30222659